Firefly Neuroscience Accepted into NVIDIA Connect Program
Firefly Neuroscience (NASDAQ: AIFF) has been accepted into the NVIDIA Connect program, marking a significant development for the AI-focused neuroscience company. The company plans to leverage NVIDIA's resources to build the world's first foundation model of the human brain using its FDA-cleared Brain Network Analytics (BNA™) technology platform, which utilizes Resting EEG and Cognitive EEG data.
The NVIDIA Connect program will provide Firefly with advanced software development resources, industry-leading frameworks, software development kits, technical training, engineering guidance, and discounts on NVIDIA software and hardware. Executive Chairman Greg Lipschitz highlighted this as an important milestone, noting that Firefly's growing BNA™ database, combined with NVIDIA's resources, positions the company uniquely for this ambitious project.
Firefly Neuroscience (NASDAQ: AIFF) è stata accettata nel programma NVIDIA Connect, segnando uno sviluppo significativo per la società di neuroscienze focalizzata sull'IA. L'azienda prevede di sfruttare le risorse di NVIDIA per costruire il primo modello fondazionale del cervello umano utilizzando la sua piattaforma di tecnologia Brain Network Analytics (BNA™) con approvazione FDA, che utilizza dati di EEG a riposo e EEG cognitivi.
Il programma NVIDIA Connect fornirà a Firefly risorse avanzate per lo sviluppo software, framework all'avanguardia nel settore, kit di sviluppo software, formazione tecnica, supporto ingegneristico e sconti su software e hardware NVIDIA. Il Presidente Esecutivo Greg Lipschitz ha sottolineato questo come un'importante pietra miliare, osservando che il crescente database BNA™ di Firefly, combinato con le risorse di NVIDIA, posiziona l'azienda in modo unico per questo ambizioso progetto.
Firefly Neuroscience (NASDAQ: AIFF) ha sido aceptada en el programa NVIDIA Connect, marcando un desarrollo significativo para la empresa de neurociencia centrada en la IA. La compañía planea aprovechar los recursos de NVIDIA para construir el primer modelo fundamental del cerebro humano utilizando su plataforma de tecnología Brain Network Analytics (BNA™) aprobada por la FDA, que utiliza datos de EEG en reposo y EEG cognitivo.
El programa NVIDIA Connect proporcionará a Firefly recursos avanzados de desarrollo de software, marcos líderes en la industria, kits de desarrollo de software, capacitación técnica, orientación en ingeniería y descuentos en software y hardware de NVIDIA. El Presidente Ejecutivo Greg Lipschitz destacó esto como un hito importante, señalando que la creciente base de datos BNA™ de Firefly, combinada con los recursos de NVIDIA, posiciona a la empresa de manera única para este ambicioso proyecto.
파이어플라이 뉴로사이언스 (NASDAQ: AIFF)가 NVIDIA Connect 프로그램에 채택되어 AI 중심의 신경 과학 회사에 중요한 발전을 이루었습니다. 이 회사는 FDA 승인 Brain Network Analytics (BNA™) 기술 플랫폼을 사용하여 인류의 첫 번째 기초 모델을 구축하기 위해 NVIDIA의 자원을 활용할 계획입니다. 이 플랫폼은 안정 상태 EEG와 인지 EEG 데이터를 사용합니다.
NVIDIA Connect 프로그램은 Firefly에 고급 소프트웨어 개발 리소스, 업계 최고의 프레임워크, 소프트웨어 개발 키트, 기술 교육, 엔지니어링 가이드, NVIDIA 소프트웨어 및 하드웨어에 대한 할인 혜택을 제공합니다. 총괄 회장 Greg Lipschitz는 이를 중요한 이정표로 강조하며 Firefly의 성장하는 BNA™ 데이터베이스와 NVIDIA의 자원 결합이 이 야심찬 프로젝트를 위해 회사를 독특하게 위치시킨다고 언급했습니다.
Firefly Neuroscience (NASDAQ: AIFF) a été acceptée dans le programme NVIDIA Connect, marquant un développement significatif pour l'entreprise de neuroscience axée sur l'IA. La société prévoit d'exploiter les ressources de NVIDIA pour construire le premier modèle fondamental du cerveau humain en utilisant sa plateforme de technologie Brain Network Analytics (BNA™) approuvée par la FDA, qui utilise des données d'EEG en repos et d'EEG cognitif.
Le programme NVIDIA Connect fournira à Firefly des ressources avancées en développement logiciel, des cadres de pointe dans l'industrie, des kits de développement logiciel, une formation technique, des conseils en ingénierie et des réductions sur les logiciels et matériels NVIDIA. Le Président Exécutif Greg Lipschitz a souligné cela comme une étape importante, notant que la base de données BNA™ en croissance de Firefly, combinée aux ressources de NVIDIA, positionne l'entreprise de manière unique pour ce projet ambitieux.
Firefly Neuroscience (NASDAQ: AIFF) wurde in das NVIDIA Connect Programm aufgenommen, was einen bedeutenden Fortschritt für das auf KI fokussierte Neurowissenschaftsunternehmen darstellt. Das Unternehmen plant, die Ressourcen von NVIDIA zu nutzen, um das weltweit erste grundlegende Modell des menschlichen Gehirns mit seiner von der FDA genehmigten Brain Network Analytics (BNA™) Technologie Plattform zu erstellen, die Ruhe-EEG- und kognitive EEG-Daten verwendet.
Das NVIDIA Connect Programm wird Firefly fortschrittliche Softwareentwicklungsressourcen, branchenführende Frameworks, Softwareentwicklungskits, technische Schulungen, Ingenieuranleitungen und Rabatte auf NVIDIA-Software und -Hardware bieten. Der Executive Chairman Greg Lipschitz hob dies als einen wichtigen Meilenstein hervor und bemerkte, dass die wachsende BNA™-Datenbank von Firefly in Kombination mit den Ressourcen von NVIDIA das Unternehmen einzigartig für dieses ehrgeizige Projekt positioniert.
- Acceptance into prestigious NVIDIA Connect program, providing access to advanced development resources
- Access to discounted NVIDIA software and hardware to accelerate development
- Strategic initiative to build first-of-its-kind brain foundation model using FDA-cleared technology
- None.
Insights
The acceptance into NVIDIA Connect Program marks a strategic technological leap for Firefly Neuroscience, with multi-faceted implications for their market position and technological capabilities. The partnership provides three critical advantages:
1. Cost-Efficiency Boost: Access to discounted NVIDIA hardware and software could significantly reduce R&D expenses, particularly important for a company with a market cap of
2. Technical Acceleration: NVIDIA's advanced AI frameworks and SDKs are particularly valuable for processing complex neurological data. The BNA™ platform's combination of Resting EEG and Cognitive ERP data creates a unique foundation for AI-driven brain modeling, which could be exponentially enhanced by NVIDIA's computational capabilities.
3. First-Mover Advantage: The initiative to build the world's first foundation model of the human brain represents a potential paradigm shift in neuroscience and AI healthcare. Similar to how large language models revolutionized NLP, a comprehensive brain foundation model could transform neurological diagnostics and treatment planning.
The market implications are substantial. While current neurological diagnostic tools often work in isolation, a foundation model could enable more sophisticated, holistic analysis of brain function. This could create new revenue streams through:
- Licensing opportunities to pharmaceutical companies for drug development
- Integration with existing healthcare diagnostic systems
- Research partnerships with academic institutions
However, investors should note that foundation model development is typically resource-intensive and time-consuming. The success will largely depend on the quality and quantity of data in Firefly's BNA™ database and their ability to effectively leverage NVIDIA's resources for large-scale AI model training.
Collaboration to provide Firefly with the technical resources to help further unleash the power of its FDA-cleared BNA™ platform
For the first time, Firefly also unveils a new strategic initiative to build the world’s first foundation model of the human brain using its BNA™ technology
KENMORE, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced its acceptance into the NVIDIA Connect program. Firefly expects to use the powerful new tools and resources provided through this prestigious program to help support a new strategic initiative to build a proprietary foundation model of the human brain using its FDA-cleared Brain Network Analytics (“BNA™”) technology platform, which harnesses Resting EEG and Cognitive EEG (ERP) data.
NVIDIA Connect brings together NVIDIA’s advanced software development resources, industry-leading frameworks and software development kits, and global ecosystem to help fuel the growth of member companies and expand the capabilities of their software development teams. Benefits include technical training and engineering guidance to support the development of products, and discounts on NVIDIA software and hardware to accelerate development and increase efficiency.
“We are honored and excited to be among the select few medtech companies – big, medium or small – to be accepted into the prestigious NVIDIA Connect program,” said Greg Lipschitz, Executive Chairman of Firefly.
“This marks the achievement of an important milestone for Firefly and comes at an extremely opportune time. As our already unparalleled BNA™ database continues to grow with each new clinical study and/or clinical assessment in which our technology is used, and we have gained vital access to the best hardware and latest resources through the NVIDIA Connect program, we believe that Firefly is now uniquely positioned to build the world’s first foundation model of the human brain,” Mr. Lipschitz added. “We look forward to updating all stakeholders, including researchers, clinicians, patients and investors, as we progress.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, secured patent protection, and achieved FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ
What is the significance of Firefly Neuroscience (AIFF) joining the NVIDIA Connect program?
What is Firefly Neuroscience's (AIFF) new strategic initiative announced in February 2025?
How does Firefly's (AIFF) BNA™ technology platform work?
What benefits will AIFF receive through the NVIDIA Connect program?
